Decera Clinical Education Neuroscience Podcast

Multiple sclerosis care is evolving fast, from what current AAN guidance emphasizes to what’s emerging in the treatment pipeline. In this episode, Patricia K. Coyle, MD, FAAN, FANA, reviews practical, patient-centered principles for MS management, including shared decision-making, realistic expectations, adherence, monitoring, and optimizing comorbidities and lifestyle factors. She also explains when to reassess and potentially switch therapy based on relapses, disability progression, and MRI activity, and highlights pipeline advances such as CNS-penetrant BTK inhibitors and other investigational approaches. Presenters:Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/4dhvLAL Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Wondering what is coming next in MS care beyond today’s disease-modifying therapies? This episode spotlights CNS-penetrant oral BTK inhibitors and the fast-moving pipeline targeting neuroinflammation, immune reset, and future CNS repair, then brings it to life with a real patient case that tests treatment selection and the decision to switch therapy. Led by Patricia K. Coyle, MD, FAAN, FANA, it is a practical listen for healthcare professionals who want a clear sense of where MS treatment is heading and why it matters now. Presenters: Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/4sau7px Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiple sclerosis (MS) is increasingly understood as a spectrum in which relapsing activity and progression can overlap, creating a need for smart, individualized use of disease-modifying therapies. Listen in to learn from Patricia K. Coyle, MD, FAAN, FANA, for a practical review of today’s MS DMT options, with a focus on high-efficacy monoclonal antibodies such as anti-CD20 therapies, how healthcare professionals think about progression concepts like PIRA and RAW, and what emerging trial designs like OCTOPUS may mean for improving treatment options in progressive MS. Presenter: Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/3PdRks4 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. For additional activities in this program including a ClinicalThought commentary, a CME/CE/CPE certified on-demand webcast and a downloadable slideset, go to: https://bit.ly/4qjcYcjFaculty:Jonathan M. Meyer, MD, DLFAPAVoluntary Clinical Professor of PsychiatryUniversity of California, San DiegoSenior Academic AdviserCalifornia Department of State HospitalsSan Diego, CaliforniaGet access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.Topics covered include:Evoke and evoke+ phase III trials of semaglutideSubcutaneous lecanemab as initiation and maintenance treatmentBlood-based biomarker assaysTrontinemab and other brain shuttlesTau targeting therapies in developmentPreventive impact of BCG and herpes zoster vaccinationThis podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk. Faculty:Anton P. Porsteinsson, MD William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and MedicineDirector, Alzheimer's Disease Care, Research and Education Program (AD-CARE)University of Rochester School of Medicine and DentistryRochester, New YorkVijay K. Ramanan, MD, PhDConsultant and Associate ProfessorDirector, Alzheimer’s Disease Treatment ClinicDepartment of NeurologyMayo ClinicRochester, Minnesota Link to obtain CME/CE credit: https://bit.ly/4999otE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for younger kids and their implementation by the patient care team.Faculty:Danielle Becker, MD, MS, FAES Division Director of EpilepsyAssociate Professor of NeurologyThe Ohio State University Wexner Medical CenterColumbus, Ohio Sarah Weatherspoon, MDAssociate Chief of Child NeurologyTuberous Sclerosis Center of Excellence, Neurology Co-DirectorLe Bonheur Children's HospitalUniversity of Tennessee Health Science CenterMemphis, TennesseeResources mentioned in this episode:Epilepsy Foundation Seizure Action Plan ToolkitCDC Managing Epilepsy Well (MEW) NetworkLink to Brain Health Hub with additional educational activities: https://bit.ly/3Y12Isx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Alireza Atri, MD, PhD, discusses his approach to patient conversations on brain health and provides advice to healthcare professionals practicing in community neurology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Alireza Atri, MD, PhD Chief Medical Officer, Banner ResearchPhoenix, Tucson and Sun City, ArizonaDirector, Banner Sun Health Research InstituteSun City, ArizonaRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Specialty Care https://bit.ly/4kqtYt5American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults https://bit.ly/44zN8qGMoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]Link to obtain CME/CE credit: https://bit.ly/44khuP5Link to Brain Health Hub with additional educational activities:https://bit.ly/4kziu6T Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, dementia expert Anton Porsteinsson, MD, discusses his approach to conversations on brain health with patients and provides guidance for HCPs practicing in community psychiatry settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Anton P. Porsteinsson, MD William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and MedicineDirector, Alzheimer’s Disease Care, Research and Education Program (AD-CARE)University of Rochester School of Medicine and DentistryRochester, New YorkRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:Mini Mental State Examination (MMSE) [Link to: https://www.psychdb.com/_media/mmse.]Mini-Cog (quick dementia screening test) [Link to: https://mini-cog.com/]MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]Alzheimer’s Association Local Chapters [Link to:https://www.alz.org/chapter-search]Local Department of Aging [Link to : https://www.thecountyoffice.com/department-of-aging/]Link to obtain CME/CE credit: https://bit.ly/3IAbyc7Link to Brain Health Hub with additional educational activities: https://bit.ly/40Jgth4  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Genevieve Neal-Perry, MD, PhD, discusses her approach to conversations on brain health with her patients in obstetrics and gynecology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Genevieve Neal-Perry, MD, PhD Robert A. Ross Distinguished ProfessorChair of Obstetrics and GynecologyUniversity of North Carolina School of MedicineChapel Hill, North CarolinaRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:Smart Patients, an online community for patients and their families [Link to: https://www.smartpatients.com/]Link to obtain CME/CE credit: https://bit.ly/4lH4BEtLink to Brain Health Hub with additional educational activities:https://bit.ly/4nJrgSG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Pierre N. Tariot, MD, discusses his approach to conversations on brain health with his patients and their family members in primary care settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Pierre N. Tariot, MDDirectorBanner Alzheimer's InstituteResearch Professor of PsychiatryUniversity of Arizona College of MedicinePhoenix, ArizonaRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:Banner Alzheimer InstituteECHO (Extension for Community Healthcare Outcomes)MoCA (Montreal Cognitive Assessment)Mini-Cog (quick dementia screening test)FDA Clears First Blood Test Used in Diagnosing Alzheimer’s DiseaseLancet Commission: Dementia Prevention, Intervention, and Care 2024Link to obtain CME/CE credit:https://bit.ly/4kk1vFsLink to Brain Health Hub with additional educational activities:https://bit.ly/3H4hoSl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Susan Scanland, MSN, CRNP, GNP-BC, CDP, discusses her approach to conversations on brain health with her patients and their family members in clinical practice as a gerontological nurse practitioner, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Susan Scanland, MSN, CRNP, GNP-BC, CDPCEO & FounderDementia Connection LLCClarks Summit, PennsylvaniaRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:Alzheimer’s Association: 2025 Alzheimer’s Disease Facts and FiguresLancet Commission: Dementia Prevention, Intervention, and Care 2024American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older AdultsAlzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Primary CareClinical Care Options: Integrating Brain Health Discussions Into Your Daily RoutineLink to obtain CME/CE credit:https://bit.ly/4mqHoaSLink to Brain Health Hub with additional educational activities:https://bit.ly/3H4hoSl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss best practices in managing people who are immunocompromised with COVID-19 in the hospital setting, including: COVID-19 burden among this populationInitial workup to assess disease severitySummary of COVID-19 guideline recommendationsA detailed patient case to illustrate key takeawaysPresenters:Michele Bartoletti, MD, PhD​Associate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), ItalyCristina Mussini, MD​Full Professor of Infectious DiseasesChief of the Department of Infectious DiseasesUniversity of Modena and Reggio EmiliaModena, ItalyMartin Witzenrath, MD, FERSMedical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benamin FranklinCharite – University of BerlinBerlin, GermanyLink to full program:https://bit.ly/4fs7HcbDownloadable slides: https://bit.ly/4imCRU5Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.Presenters: Robert O. Cotes, MD, DFAPAAssociate Professor and Distinguished PhysicianDirector, Clinical & Research Program for Psychosis at Grady Health SystemDirector, Project ARROW at Grady Health SystemDepartment of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlanta, GeorgiaDavid R. Goldsmith, MD, MScAssociate ProfessorDirector, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) LabCo-Director, Clinical & Research Program for Psychosis at Grady Health SystemDirector, PSTAR Clinic at Grady Memorial HospitalFaculty, Emory Behavioral Immunology ProgramCo-Director, Psychiatry Residency Research TrackDepartment of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlanta, GeorgiaThis content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals. Link to full program: https://bit.ly/414XkY4 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.orgOngoing collection and analysis of longitudinal data within the Rett Syndrome Natural History StudyEfficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesineSeveral early ongoing gene therapy trialsDr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.Presenters: David N. Lieberman, MD, PhDDirector, Comprehensive Rett Syndrome ClinicDepartment of NeurologyBoston Children's HospitalBoston, MassachusettsEric Marsh, MD PhDClinical Director, Orphan Disease CenterDirector (MPI), CHOP/Penn IDDRCProfessor, Departments of Neurology and PediatricsDivision of NeurologyChildren’s Hospital of PhiladelphiaPerelman School of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaThis content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:https://bit.ly/4fJRRL0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim Credit - https://bit.ly/3OByCaEIn this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settingsThe role of antiseizure medications in DEE treatment managementThe nonpharmacological treatment options available to patients with DEEsThe emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s diseaseResults from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequencyThe future of soticlestat as a treatment option for pediatric patients with DEEsPresenters:Jonathan J. Halford, MDProfessorDirector, Translational Research UnitDepartment of NeurologyMedical University of South CarolinaCharleston, SCCecil Hahn, MD, MPH, FRCPCProfessorPediatric EpileptologistUniversity of TorontoToronto, Ontario, CanadaContent based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.Link to full program: https://bit.ly/45UUpQy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim Credit - https://bit.ly/3wbVkA1In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:Overview of brain cholesterol and its function in the bodyPathogenesis potential for certain diseases via brain cholesterolEmerging research on a cholesterol synthase inhibitor as a novel therapyThe future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseasesPresenters:Jonathan J. Halford, MDProfessorDirector, Translational Research UnitDepartment of NeurologyMedical University of South CarolinaCharleston, SCH. Steve White, PhDProfessor, Department of PharmacyCo-Director, Center for Epilepsy Drug DiscoverySchool of PharmacyUniversity of WashingtonSeattle, Washington Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:Defining AD and MCI and their clinical presentationHow to diagnose AD vs MCIReimbursement landscape for current diagnosing and monitoring toolsPrecision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI Presenters:Marwan Sabbagh, MDProfessor of NeurologyAlzheimer’s and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaRichard Isaacson MDDirector of the Institute for Neurodegenerative DiseasesFlorida  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care. Presenters:Anita Clayton, MDDavid C. Wilson Professor and ChairDepartment of Psychiatry and Neurobehavioral SciencesProfessor of Clinical Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, VirginiaThis podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.Link to full program:https://bit.ly/3YdPMPa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.      Presenters:David N. Lieberman, MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children’s HospitalBoston, MassachusettsJeffrey Neul, MD, PhDDirectorPediatricsVanderbilt University Medical CenterNashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here: bit.ly/3JR4qq5.For additional activities in this program, visit bit.ly/3JR4qq5  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rett syndrome affects many organ systems, and each patient has individual symptoms and experiences—there is no “one-size-fits-all” treatment approach. In this podcast episode, Rett syndrome experts David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, discuss some of the more common manifestations of Rett syndrome and current management strategies. While covering manifestations such as epilepsy, behavioral issues, and gastrointestinal distress, they highlight the value of a team approach to help the patient thrive. Throughout their conversation, Drs Lieberman and Standridge weave in real-world examples of interactions they have had with families of patients with Rett syndrome and offer insights on communication strategies for different aspects of management.Presenters:David N. Lieberman MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children’s HospitalBoston, MassachusettsShannon Standridge, DO, MPHProfessorDivision of NeurologyVinaya Rett Syndrome and Related Spectrum Disorders ClinicCincinnati Children’s Hospital Medical CenterCincinnati, OhioThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here: http://bit.ly/41CeaePFor additional activities in this program, visit http://bit.ly/3lXuzda Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.Presenters:David N. Lieberman MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children's HospitalBoston, MassachusettsJeffrey Neul MD, PhDDirectorPediatricsVanderbilt University Medical CenterNashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here:https://bit.ly/3WjtMjAFor additional activities in this program, visit:https://bit.ly/3kfAn0U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.Administering LAI Into Dorsal Gluteal Site: https://bit.ly/3XjSm5aAdministering LAI Into Deltoid Site: https://bit.ly/3Xlyq1LAdministering LAI Into Abdominal Site: https://bit.ly/3wgGJ2ZPresenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkAdam Lowy, MDStaff PsychiatristEllenhornLos Angeles, CaliforniaThis activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.For additional activities in this program, visit:https://bit.ly/3iM0HiP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.Presenters:Aatif Husain, MDProfessorDivision of Epilepsy, Sleep and Clinical NeurophysiologyDepartment of NeurologyDuke University Medical CenterDurham, North CarolinaJohn Stern, MDProfessorNeurologyGeffen School of Medicine, UCLADirectorEpilepsy Clinical ProgramUCLA Department of NeurologyLos Angeles, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.For additional activities in this program, visit https://bit.ly/3GiLlu4. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.Presenters:Marwan Sabbagh, MD, FAANProfessor of NeurologyAlzheimer's and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaMarta San Luciano, MD, MS, FAANAssociate Professor of NeurologyUniversity of California, San FranciscoAttending NeurologistNeurology/Movement Disorders and Neuromodulation CenterUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.For additional activities in this program, visithttp://bit.ly/3tPMqnr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.Presenters:Christoph U. Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellNew York, New YorkProfessor of Child and Adolescent PsychiatryCharité – Universitätsmedizin BerlinBerlin, GermanyJohn M. Kane, MDVice President for Behavioral Health ServicesNorthwell HealthChairman of PsychiatryZucker Hillside HospitalQueens, New YorkChairman of PsychiatryProfessor of Psychiatry and Molecular MedicineZucker School of Medicine at Hofstra/NorthwellHempstead, New YorkFor more programs in this series, visit:https://bit.ly/3AhRXau Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various  neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3ft1rYI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkCharles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaStuart Isaacson, MDDirectorParkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, FloridaClinical Associate Professor of NeurologyFIU Herbert Wertheim College of MedicineMiami, FloridaGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramRajesh Pahwa, MDChief, Parkinson and Movement Disorder DivisionDirector, Parkinson Foundation Center of ExcellenceUniversity of Kansas Medical CenterKansas City, KansasFor more programs in this series, visit: https://bit.ly/3Bg0oTv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.Presenters:Joseph F. Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkRoger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3ft1rYI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.Presenters:Robert O. Cotes, MDAssociate ProfessorDepartment of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlanta, GeorgiaJonathan M. Meyer, MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis Program Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.Presenters:Diana O. Perkins, MD, MPHProfessor, PsychiatryUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaRajiv Tandon, MDEmeritus Professor of PsychiatryDepartment of PsychiatryWestern Michigan University Homer Stryker MD College of MedicineKalamazoo, MichiganThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.For more programs in this series, visit:https://bit.ly/3yOL8f7 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression. Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit: https://bit.ly/3TClDqb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.Presenters:Joseph P. McEvoy MDProfessorPsychiatry and Health BehaviorPsychiatristAugusta UniversityAugusta, GeorgiaLeslieThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.For more programs in this series, visit:https://bit.ly/3dUCVi6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis. Presenters:Greg W. Mattingly, MDAssociate Clinical Professor PsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit: https://bit.ly/3TClDqb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Get answers to the questions that you and your colleagues have asked! In this episode, Charles DeBattista, MD, provides answers to audience questions that were submitted at 2 recent Psychiatry Update meetings. His thoughtful responses cover your questions on differential diagnosis, initiating pharmacotherapy, medication management, and more. Moderators Amber Hoberg, PMHNP, and Greg W. Mattingly, MD, provide complementary commentary throughout the Q&A session, adding interprofessional perspective to the activity.Presenters:Charles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaAmber Hoberg, PMHNPNurse PractitionerMorningStar Family MedicineFloresville, TexasGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3cX8ebyRegister for our Psychiatry Update 2022 series. This program is free and will offer up to 5 CME/CE credits. For physicians (MD, DO), psychiatry specialist NPs and PAs, pharmacists, social workers, and psychologists, register at:https://bit.ly/3Q1WLWRFor NPs and PAs in primary care/other specialties, register at:https://bit.ly/3Jf54Ma Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer, MDVoluntary Clinical ProfessorDepartment of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.For more programs in this series, visit: https://bit.ly/3AhRXau Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics. Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriCharles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit: https://bit.ly/3bPCiVH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the impact of tardive dyskinesia on social and functional domains and the benefits of proper assessment and treatment of tardive dyskinesia in improving patient quality of life in these areas.Presenters:Diana Perkins, MD, MPHProfessor of Psychiatry University of North Carolina School of MedicineChapel Hill, North Carolina Martha Sajatovic, MDProfessor of Psychiatry and NeurologyDepartments of Psychiatry and NeurologyCase Western Reserve University School of MedicineCleveland, OhioLink to full program:https://bit.ly/3GkJmUS  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.  Presenters:Sanjay J. Mathew, MDProfessor and Vice Chair for ResearchPsychiatry and Behavioral SciencesBaylor College of MedicineHouston, TexasRoger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaLink to full program:https://bit.ly/3syJzh2   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss who PCPs should screen for TD, adverse effects PCPs should put on their radar screen when monitoring patients on antipsychotics, how TD is different from parkinsonism, the use of anticholinergics, and which patients have an increased risk for TD when on antipsychotics.  Presenters:Greg Mattingly, MDAssociate Clinical ProfessorPsychiatry, PsychopharmacologyWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriW. Clay Jackson, MD, DipTh  Assistant Professor of Clinical Family Medicine & PsychiatryCollege of MedicineUniversity of TennesseeDirectorPalliative CareWest Cancer CenterMemphis, TennesseeLink to full program:https://bit.ly/2RM8hfM  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.  Podcast from Clinical Care Options (CCO) with Joseph Goldberg, MD, and Greg Mattingly, MD, on the role of antidepressants in bipolar disorder.Presenters:Joseph Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkGreg Mattingly, MDAssociate Clinical ProfessorPsychiatry, PsychopharmacologyWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, Missouri  Link to full program:https://bit.ly/3syJzh2  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.  Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkManpreet K. Singh, MD, MSAssociate Professor of Psychiatry and Behavioral SciencesStanford UniversityStanford, CaliforniaLink to full program:https://bit.ly/3syJzh2  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.Presenters:Greg Mattingly, MDAssociate Clinical ProfessorPsychiatry, PsychopharmacologyWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriW. Clay Jackson, MD, DipTh  Assistant Professor of Clinical Family Medicine & PsychiatryCollege of MedicineUniversity of TennesseeDirectorPalliative CareWest Cancer CenterMemphis, TennesseeLink to full program:https://bit.ly/2RM8hfM  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.Presenters:John M. Kane, MDProfessor and ChairmanDepartment of PsychiatryDonald and Barbara Zucker School of Medicine at Hofstra/NorthwellGlen Oaks, New YorkRebecca S. Roma, MDMedical DirectorREACH, LLCPittsburgh, PennsylvaniaLink to full program:https://bit.ly/2RM8hfM  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkJoseph P. McEvoy, MDProfessorPsychiatry and Health BehaviorPsychiatristAugusta UniversityAugusta, GeorgiaLink to full program:https://bit.ly/2RM8hfM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  Presenters:Roger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaJoseph Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkContent based on an online CME program supported by an educational grant from Neurocrine Biosciences.Link to full program:https://bit.ly/2RM8hfM  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.